This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MorphoSys Balans Gezondheid

Financiële gezondheid criteriumcontroles 2/6

MorphoSys has a total shareholder equity of €-261.7M and total debt of €1.7B, which brings its debt-to-equity ratio to -658%. Its total assets and total liabilities are €1.8B and €2.1B respectively.

Belangrijke informatie

-658.0%

Verhouding schuld/eigen vermogen

€1.72b

Schuld

Rente dekkingsration/a
Contant€630.77m
Aandelen-€261.67m
Totaal verplichtingen€2.09b
Totaal activa€1.83b

Recente financiële gezondheidsupdates

Recent updates

MorphoSys: Hold Rating Until The Novartis Deal Closes

May 01

Novartis And MorphoSys Are A Perfect Match

Feb 06

MorphoSys: Positive Pelabresib Data Finally Unlocking Upside

Jan 18

MorphoSys updates Q2 & FY22 guidance below prior provided levels

Jul 26

MorphoSys May Not Recover From Adventurous Constellation Buyout

May 04

Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte

Jan 28

Incyte and MorphoSys presents new three-year data for blood cancer therapy

Jun 04

MorphoSys reports Q1 results

May 05

MorphoSys AG appoints Sangamo 's Sung Lee as new CFO

Jan 06

MorphoSys AG (MOR) Investor Presentation - Slideshow

Dec 08

MorphoSys AG 2020 Q3 - Results - Earnings Call Presentation

Nov 22

MorphoSys reports Q3 results

Nov 11

Analyse van de financiële positie

Kortlopende schulden: MOR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Langlopende schulden: MOR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: MOR has negative shareholder equity, which is a more serious situation than a high debt level.

Schuld verminderen: MOR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: MOR has sufficient cash runway for more than a year based on its current free cash flow.

Voorspelling contante baan: MOR has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 35.7% each year


Ontdek gezonde bedrijven